Compile Data Set for Download or QSAR
maximum 50k data
Found 150 Enz. Inhib. hit(s) with all data for entry = 3353
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397684((S)-N-(5-(6-cyano-5-((1-((2,2-difluoroethyl)(methy...)
Affinity DataIC50:  2.51nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397657((R)-N-(5-(4-cyano-3-((1-(dimethylamino)-1-oxobutan...)
Affinity DataIC50:  3.16nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397717(N-(5-(6-cyano-5-(((S)-1-((2,2-difluoroethyl)(methy...)
Affinity DataIC50:  3.98nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397772((R)-N-(5-(6-cyano-5-((2-(2-(difluoromethyl)pyrroli...)
Affinity DataIC50:  5.01nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397679((R)-N-(5-(6-cyano-5-((2-oxo-2-(2-(trifluoromethyl)...)
Affinity DataIC50:  6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397665((S)-N-(5-(4-cyano-3-((1-(dimethylamino)-4,4-difluo...)
Affinity DataIC50:  6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397638((S)-N-(5-(4-cyano-3-((1-(dimethylamino)-4-methoxy-...)
Affinity DataIC50:  6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397750(N-(5-(6-cyano-5-(((2S)-1-((1,1-difluoropropan-2-yl...)
Affinity DataIC50:  7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397777(N-(5-(6-cyano-5-(((S)-1-((2,2-difluoroethyl)(methy...)
Affinity DataIC50:  7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397639(US9994547, Example 8.0)
Affinity DataIC50:  7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397637(N-(5-(4-cyano-3-((1-(dimethylamino)-1-oxobutan-2-y...)
Affinity DataIC50:  7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397632((S)-N-(5-(4-cyano-3-((1-(dimethylamino)-1-oxopropa...)
Affinity DataIC50:  7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397677(N-(5-(6-cyano-5-((1-((2,2-difluoroethyl)(methyl)am...)
Affinity DataIC50:  10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397685((S)-N-(5-(6-cyano-5-((1-((2-fluoroethyl)(methyl)am...)
Affinity DataIC50:  10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397643((S)-N-(5-(4-cyano-3-((1-(ethyl(methyl)amino)-1-oxo...)
Affinity DataIC50:  10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397681((S)-N-(5-(6-cyano-5-((1-((cyanomethyl)(methyl)amin...)
Affinity DataIC50:  12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397634(US9994547, Example 3.0)
Affinity DataIC50:  12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397720(N-(5-(6-cyano-5-(((S)-1-(((S)-1-cyanoethyl)(methyl...)
Affinity DataIC50:  12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397672(N-(5-(6-cyano-5-((1-(methyl(2,2,2-trifluoroethyl)a...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397703(N-(5-(6-cyano-5-((2-((2,2-difluoroethyl)(2-hydroxy...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397712(N-(5-(6-cyano-5-(((S)-1-((S)-3-cyanomorpholino)-1-...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397660(N-(5-(4-cyano-3-((1-((2-hydroxyethyl)(methyl)amino...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397727((S)-N-(5-(6-cyano-5-((2-oxo-2-(2-(trifluoromethyl)...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397738((1R,2R)-N-(5-(6-cyano-5-(((S)-1-(dimethylamino)-1-...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397781((S)-N-(5-(6-cyano-5-((1-((2,2-difluoroethyl)(methy...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397713(N-(5-(6-cyano-5-((2-((2,2-difluoroethyl)(2-methoxy...)
Affinity DataIC50:  15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397674(N-(5-(6-cyano-5-((1-((cyanomethyl)(methyl)amino)-1...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397678(N-(5-(6-cyano-5-((1-((2-fluoroethyl)(methyl)amino)...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397687((S)-N-(5-(6-cyano-5-((1-((2-fluoroethyl)(methyl)am...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397700(N-(5-(6-cyano-5-(((2S)-1-((1-cyanoethyl)(methyl)am...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397722(N-(5-(6-cyano-5-(((S)-1-((S)-3-methylmorpholino)-1...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397739((1R,2S)-N-(5-(6-cyano-5-(((S)-1-(dimethylamino)-1-...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397743((S)-N-(5-(6-cyano-5-((1-(ethyl(methyl)amino)-1-oxo...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397745((S)-N-(5-(6-cyano-5-((1-((2,2-difluoroethyl)amino)...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397760((S)-N-(5-(6-cyano-5-((1-(dimethylamino)-1-oxopropa...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397770(N-(5-(6-cyano-5-(((S)-1-((S)-3-fluoropyrrolidin-1-...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397650((S)-N-(5-(4-cyano-3-((1-((2-hydroxyethyl)(methyl)a...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397654((S)-N-(5-(4-cyano-3-((1-(dimethylamino)-1-oxobutan...)
Affinity DataIC50:  20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397686(N-(5-(6-cyano-5-(((S)-1-((R)-2-cyanopyrrolidin-1-y...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397719(N-(5-(6-cyano-5-(((S)-1-(((R)-1-cyanoethyl)(methyl...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397744(N-(5-(6-cyano-5-((2-((2S,4R)-4-(hydroxymethyl)-2-(...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397768((S)-N-(5-(4-cyano-3-((1-(dimethylamino)-1-oxopropa...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397760((S)-N-(5-(6-cyano-5-((1-(dimethylamino)-1-oxopropa...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397767((S)-N-(5-(4-cyano-3-((1-(dimethylamino)-3-hydroxy-...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397757(N-(5-(4-cyano-3-((2-(methyl(2,2,2-trifluoroethyl)a...)
Affinity DataIC50:  25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397676((R)-N-(5-(6-cyano-5-((2-(2-cyanopyrrolidin-1-yl)-2...)
Affinity DataIC50:  31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397695(N-(5-(6-cyano-5-((2-oxo-2-(2-(trifluoromethyl)oxaz...)
Affinity DataIC50:  31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397671(N-(5-(6-cyano-5-((2-(methyl(2,2,2-trifluoroethyl)a...)
Affinity DataIC50:  31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397780((S)-N-(5-(6-cyano-5-((1-((2,2-difluoroethyl)(methy...)
Affinity DataIC50:  31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase TBK1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397649(N-(5-(4-cyano-3-((1-(dimethylamino)-3-hydroxy-1-ox...)
Affinity DataIC50:  31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 150 total ) | Next | Last >>
Jump to: